Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Mar. 31, 2024
shares
| |
| Trading Arrangements, by Individual | |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| Steven Stein [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | Steven Stein, our Executive Vice President and Chief Medical Officer, adopted a trading plan on February 20, 2024 providing for the sale of up to an aggregate of 20,147 shares of our common stock until December 31, 2024.
|
| Name | Steven Stein |
| Title | Executive Vice President and Chief Medical Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | February 20, 2024 |
| Arrangement Duration | 315 days |
| Aggregate Available | 20,147 |
| Barry Flannelly [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | Barry Flannelly, our Executive Vice President and General Manager, North America, adopted a trading plan on February 20, 2024 providing for the sale of up to an aggregate of 52,931 shares of our common stock until December 31, 2024.
|
| Name | Barry Flannelly |
| Title | Executive Vice President and General Manager, North America |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | February 20, 2024 |
| Arrangement Duration | 315 days |
| Aggregate Available | 52,931 |
| Thomas Tray [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | Thomas Tray, our Vice President, Chief Accounting Officer, adopted a trading plan on March 7, 2024 providing for the sale of up to an aggregate of 1,093 shares of our common stock until June 28, 2024.
|
| Name | Thomas Tray |
| Title | Vice President, Chief Accounting Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | March 7, 2024 |
| Arrangement Duration | 113 days |
| Aggregate Available | 1,093 |